Analyzing Aytu BioPharma (AYTU) and Its Competitors

Aytu BioPharma (NASDAQ:AYTU – Get Free Report) is one of 894 publicly-traded companies in the “Pharmaceuticals” industry, but how does it contrast to its rivals? We will compare Aytu BioPharma to similar businesses based on the strength of its dividends, risk, institutional ownership, earnings, profitability, analyst recommendations and valuation.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Aytu BioPharma and its rivals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aytu BioPharma 2 0 2 0 2.00
Aytu BioPharma Competitors 7845 13797 25807 1039 2.41

Aytu BioPharma presently has a consensus price target of $14.50, suggesting a potential upside of 714.61%. As a group, “Pharmaceuticals” companies have a potential upside of 24.15%. Given Aytu BioPharma’s higher probable upside, equities analysts clearly believe Aytu BioPharma is more favorable than its rivals.

Risk & Volatility

Aytu BioPharma has a beta of 0.24, indicating that its stock price is 76% less volatile than the S&P 500. Comparatively, Aytu BioPharma’s rivals have a beta of -0.04, indicating that their average stock price is 104% less volatile than the S&P 500.

Valuation and Earnings

This table compares Aytu BioPharma and its rivals gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Aytu BioPharma $57.57 million -$14.25 million -1.07
Aytu BioPharma Competitors $18.33 billion $3.19 billion 562.77

Aytu BioPharma’s rivals have higher revenue and earnings than Aytu BioPharma. Aytu BioPharma is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Aytu BioPharma and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Aytu BioPharma -24.76% -56.54% -13.14%
Aytu BioPharma Competitors -2,398.26% -203.62% -15.08%

Insider and Institutional Ownership

33.5% of Aytu BioPharma shares are held by institutional investors. Comparatively, 32.7% of shares of all “Pharmaceuticals” companies are held by institutional investors. 6.1% of Aytu BioPharma shares are held by company insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Aytu BioPharma rivals beat Aytu BioPharma on 7 of the 13 factors compared.

About Aytu BioPharma

(Get Free Report)

Aytu BioPharma, Inc. is a specialty pharmaceutical company focused on developing and commercializing prescription treatments. Its business has centered on medicines for attention-deficit/hyperactivity disorder (ADHD) and other pediatric conditions. The company’s product portfolio has included ADHD medications such as Adzenys XR-ODT, an orally disintegrating amphetamine tablet, and Cotempla XR-ODT, an extended-release methylphenidate tablet. Aytu has also marketed treatments for other pediatric needs, including allergies.

Receive News & Ratings for Aytu BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aytu BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.